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Abstract
Background: Few studies are available evaluating the impact of rapid-acting insulin analogues on long-term
diabetes outcomes. Our aim was to compare the use of rapid-acting insulin analogues versus human regular insulin
in relation to the occurrence of diabetic complications in a cohort of diabetic patients through the analysis of
administrative databases.
Methods: A population-based cohort study was conducted using administrative data from four local health authorities
in the Abruzzo Region (900,000 inhabitants). Diabetic patients free of macrovascular disease at baseline and treated
either with human regular insulin or rapid-acting insulin analogues were followed for a maximum of 3 years. The
incidence of diabetic complications was ascertained by hospital discharge claims. Hazard ratios (HRs) and 95% CIs
of any diabetic complication and macrovascular, microvascular and metabolic complications were estimated
separately using Cox proportional hazard models adjusted for patients’ characteristics and anti-diabetic drug use.
Propensity score matching was also used to adjust for significant difference in the baseline characteristics between
the two treatment groups.
Results: A total of 2,286 patients were included: 914 receiving human regular insulin and 1,372 rapid-acting insulin
analogues. During the follow-up, 286 (31.3%) incident events occurred in the human regular insulin group and 235
(17.1%) in the rapid-acting insulin analogue group. After propensity score-based matched-pair analyses, rapid-acting
insulin analogues users had a HR of 0.73 (0.58–0.92) for any diabetes-related complication and HRs of 0.73 (0.55–
0.93) and 0.55 (0.32–0.96) for macrovascular and metabolic complications respectively, as compared with human
regular insulin users. No difference between the two groups was found for microvascular complications.
Conclusions: Our findings suggest that the use of rapid-acting insulin analogues is associated with a lower risk of
cardiovascular and metabolic complications compared with human regular insulin use.
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Introduction
The major challenge in diabetes management is preventing
or delaying the progression of diabetes-related complications.
The landmark trials in type 1 [1,2] and type 2 [3,4] diabetic
patients have demonstrated a strong inverse relationship
between blood glucose levels and the occurrence of long-term
microvascular complications.
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Recently an increasing body of evidence, not yet fully
supported by randomized clinical trials, has suggested that
postprandial hyperglycemia is directly implicated in
cardiovascular complications [5-7]. The hypothesis is that a
better control of postprandial glucose (PPG) levels may be an
important therapeutic target in the prevention of cardiovascular
complications in diabetic patients.
The use of rapid-acting insulin analogues (Lispro, Aspart,
Glulisine) provides lower postprandial glucose excursions in
people with diabetes [8-11]. Nevertheless their effects on long-
term outcomes are unknown.
A recent observational study showed that the rapid-acting
insulin analog gluslisine was associated with a reduced
incidence of macro- and microvascular events in patients with
type 2 diabetes in comparison with human regular insulin [12].
However, the primary care setting used in that study didn’t
allow to capture all events but only those registered by the
general practitioners (GPs).
The aim of this study is therefore to compare the use of
rapid-acting insulin analogues and human regular insulin in
relation to the first occurrence of any diabetes-related
complication in a cohort of diabetic patients without
macrovascular disease at baseline through the analysis of
administrative databases.
Methods
We conducted a retrospective, population-based cohort
study using administrative data from four local health
authorities in the Abruzzo Region of Central Italy, that comprise
about 900,000 inhabitants (68% of the overall regional
population).
Details regarding data sources and study design have been
published previously [13]. Briefly, a record-linkage analysis of
outpatient drug prescriptions, hospital discharges, prescriptions
for laboratory tests, services use and specialistic consultations
and the civil registry was performed including data from
January 1, 2005 to December 31, 2008. All information was
linked through a unique and anonymous personal identification
code. In order to protect the patient’s privacy the inverse
process was prevented by the deletion of the conversion table.
Because this automated system is anonymous, neither ethical
committee approval nor informed consent was required.
Furthermore the anonymous data file is routinely used by the
regional health authorities for epidemiological and
administrative purposes. Permission to use it for the present
study was granted by the responsible authority.
Study population
A flow chart of the study population selection is depicted in
Figure 1. From the source population we identified individuals
with at least four prescriptions of insulin agents between
January 1, 2005 and December 31, 2005 (baseline year).
At baseline, we excluded patients if they had (i) at least one
prescription of antiplatelets (excluding low-dose aspirin),
pentoxifylline or nitrates, which are commonly used for the
treatment of ischemic cardiovascular diseases, or a diagnosis
of macrovascular disease in hospital discharge or procedure
codes reported on prescriptions for services use [13]; (ii) no
prescription of either human regular insulin or rapid-acting
insulin analogues;(iii) prescriptions of both human regular
insulin or rapid-acting insulin analogues during the whole study
period (January 1, 2005 to December 31, 2008). Individuals
who met the criteria were divided into two mutually exclusive
groups (study cohorts): those treated with human regular
insulin and those treated with rapid-acting insulin analogues
throughout the entire follow-up. In both groups the bolus insulin
was used alone or in combination with other types of insulin
(premixed insulin and basal insulin) or oral hypoglycemic
drugs, or both.
Each individual accumulated person-years of follow-up from
January 1, 2006 until the date of hospital admission for any
diabetic complications, censoring (death or emigration), or
December 31, 2008 (i.e. the end of the follow-up), whichever
occurred first.
Covariates
For each patient the following potential confounders were
assessed at baseline: age, sex, metabolic and microvascular
complications, and concomitant drugs. The algorithm
developed for identifying the microvascular and metabolic
complications at baseline (reasonable proxy measure of
severity and duration of diabetes) has been described
elsewhere [13]. Prescriptions of other anti-diabetic drugs
(intermediate/long-acting insulins, premixed insulins and
different oral hypoglycemic agents), low-dose aspirin,
antiarrhythmic agents, antihypertensive agents and lipid-
lowering agents were also included. For each anti-diabetic
agent (insulins and oral hypoglycemics) we further calculated
the mean daily dose based on drug supplies through the total
follow-up and categorized them into quartiles.
Finally, we also assessed the number of hemoglobin A1C
tests performed by patients during the follow-up.
Outcomes
The primary outcome of this study was the first occurrence of
any diabetes-related complication during the follow-up. The
secondary outcome was the first occurrence of specific clinical
conditions including macrovascular, microvascular and
metabolic complications [13]. To evaluate the risk of
hospitalization we used only ordinary hospital admissions (i.e.
day hospital admissions were excluded). Long-term
complications were captured as an outcome of interest only if
recorded as primary discharge diagnosis.
Statistical analysis
The chi-square test (categorical variables) or unpaired t-test
(continuous variable) for numerical variables were used to
determine whether there were differences between baseline
characteristics of patients treated with human regular insulin or
rapid-acting insulin analogues.
Two statistical methods were used to evaluate the risk
associated with bolus insulin treatment. First, we constructed
Cox proportional hazards models to derive hazard ratios (HRs)
and 95% confidence intervals (CIs), using the human regular
insulin group as the reference group. Estimates were adjusted
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for age, gender, previous microvascular and metabolic
complications, number of HbA1c tests, use of low-dose aspirin,
antiarrhythmics agents, antihypertensive and lipid-lowering
agents and mean daily dosage of anti-diabetic drugs in
quartiles. Second, we performed a propensity-score (PS)
matched Cox proportional hazard analysis. Specifically, we
used PS analysis to identify subsamples of the two treatment
groups (human regular insulin and the rapid-acting insulin
analogues) that are “balanced” on all covariates listed in Table
1. This approach has been shown to be efficient for bias
Figure 1.  Patient selection flowchart.  
doi: 10.1371/journal.pone.0079762.g001
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reduction due to the lack of randomization [14]. A flow diagram
for identifying and creating the matched sample, together with
the standardized differences in covariate means and
prevalence between the two treatment groups, is available in
the Supporting Information [see Figure S1; Figure S2].
Kaplan-Meier estimates were used to generate time to event
curves for the primary- and secondary outcomes. In the
unmatched sample, survival curves were compared across the
two treatment groups by the log-rank test. In the matched
sample, survival curves were constructed using paired Kaplan-
Meier estimates and compared using the Klein-Moeschberger
test.
All analyses were performed using R (A Language and
Environment for Statistical Computing, Release 2.14.1; R
Foundation for Statistical Computing, http://www.R-project.org)
and SPSS software version 17.1 for Windows (SPSS Inc,
Chicago, IL, USA).
Results
Baseline characteristics
Overall, 2,286 patients were included into the analyses: 914
in the human regular insulin group and 1,372 in the rapid-acting
insulin analogue group. The total number of patient-years
accumulated was 2,084 for the human regular insulin users
and 3,675 for the rapid-acting insulin analogue users.
As shown in Table 1, the two study groups had different
characteristics at baseline. Compared with patients in the
rapid-acting insulin analogue group, those in the human regular
insulin group were older, more likely to be women and more
likely to receive low-dose aspirin, antihypertensive drugs and
antiarrhythmic agents but less likely to receive lipid lowering
agents and oral hypoglycemic agents (metformin,
sulphonylureas, thiazolidenediones) and less likely to perform
HbA1c tests. The mean daily dosage for all insulin formulations
was 1.13±0.64 SD in the rapid-acting insulin analogue group
vs. 1.03±0.80 SD in the human regular insulin group (p=0.001).
For oral hypoglycemic, the mean daily dosage was 0.72±0.68
SD in the rapid-acting insulin analogue group vs. 0.58±0.54 in
the human regular insulin group (p=0.002) At baseline, no
difference was found between the two groups in the prevalence
of microvascular and metabolic complications.
Using the PS approach, 566 patients treated with human
regular insulin were matched with an equal number of patients
receiving rapid-acting insulin analogues. Baseline
characteristics were balanced for all covariates in these
matched cohorts (Table 1). No difference between the two PS
matched cohort was found for the mean daily dose of insulin
and oral hypoglycemic agents.
Follow-up
During the 3-year follow-up, there were 286 incident events
(31.3%) in the human regular insulin group and 235 (17.1%) in
the rapid-acting insulin analogue group, with a difference
between the two treatment groups in the cumulative HR for any
diabetic complications that increased over time (p<0.0001 by
the log-rank test) (Figure 2).
Table 1. Baseline characteristics and propensity score
matched baseline characteristics of patients treated with
human regular insulin or rapid-acting insulin analogues.
 Unmatched cohorts
Propensity-score
matched cohorts
 
Human
regular
insulin
Rapid-
acting
Insulin
Analogues P
Human
regular
insulin
Rapid-
acting
Insulin
Analogues P
N 914 1,372  566 566  
Age, yearsa 68.8±15.4 58.5±17.4 <0.0001 65.1 ±16.2
65.3 ±
14.8 0.800
Female, n (%) 522 (57.1) 725 (52.8) 0.045 304(53.7)
307
(54.2) 0.856
Patients with 1 or
more diabetic
complications, n
(%)
      
Metabolic 23 (2.5) 25 (1.8) 0.257 12(2.1) 14 (2.5) 0.860
Microvascular 214 (23.4) 290 (21.1) 0.198 143(25.3)
141
(24.9) 0.892
Patients with at
least 1 prescription
of, n (%)
      
Low-dose aspirin 390 (42.7) 511 (37.2) 0.009 237(41.9)
247
(43.6) 0.557
Antiarrhythmic
agents 127 (13.9) 109 (7.9) <0.0001
56
(9.9) 54 (9.5) 0.835
Antihypertensive
agents 655 (71.7) 876 (63.8) <0.0001
404
(71.4)
395
(69.8) 0.557
Lipid-lowering
agents 213 (23.3) 409 (29.9) 0.001
159
(28.1)
169
(29.9) 0.504
Other anti-diabetic
drugs, n(%)       
Intermediate/Long-
acting insulin 379 (41.5) 448 (32.7) <0.0001
280
(49.5)
270
(47.7) 0.534
Glargine 96 (10.5) 793 (57.8) <0.0001 96(17) 98 (17.3) 0.715
Premixed 345 (37.7) 171 (12.5) <0.0001 110(19.4)
117
(20.7) 0.531
Oral
hypoglycemics 267 (29.2) 499 (36.4) <0.0001
185
(32.7)
209
(36.9) 0.130
Metformin 241 (26.4) 420 (30.6) 0.027 165(29.2)
167
(29.5) 0.899
Sulphonylureas 58 (6.3) 132 (9.6) 0.004 49(8.7) 46 (8.1) 0.745
Thiazolidinediones 7 (0.8) 25 (1.8) 0.022 6(1.1) 7 (1.2) 0.782
Other
hypoglycemics 56 (6.1) 105 (7.7) 0.154
41
(7.2) 47 (8.3) 0.501
Average number of
HbA1c tests per
yeara
0.7 ± 1.5 1.1 ± 1.3 <0.001 0.7 ±1.1 0.8 ± 1.2 0.364
a Data are mean ±SD.
doi: 10.1371/journal.pone.0079762.t001
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After multivariable adjustments, using human regular insulin
group as the reference group, the HR was 0.56 (95% CI:
0.45-0.69) for any diabetic complications in the rapid-acting
insulin analogue group. Regardless of secondary outcomes,
we found 203 macrovascular events (22.2%) in the human
regular insulin group and 147 (10.7%) in the rapid-acting insulin
analogue group, with a significant reduction in macrovascular
complications associated with the use of rapid-acting insulin
analogues (HR=0.56; 95% CI:0.43-0.72) (Table 2). Among
macrovascular events, a highly significant reduction was
observed for each specific clinical condition in the rapid-acting
insulin analogue users. A statistically significant difference was
also found in the risk of metabolic complications. Among these,
only the difference in hyperglycemic events remained
significant after multivariate adjustments. Conversely, no
difference between the two groups was found for microvascular
disease rates (Table 2).
The PS matched Cox models supported these results
(Figure S3). Specifically, the differences between the two
groups in relation to the risk of any diabetic (HR=0.73; 95% CI:
0.58-0.92), macrovascular (HR=0.73; 95% CI:0.55-0.95) and
metabolic complications (HR=0.55; 95% CI:0.32-0.94)
remained statistically significant. However among
macrovascular events, no difference between the two groups
was found for any specific clinical condition. The analysis
confirmed the lack of statistical significance for the difference in
microvascular complication rates (HR=0.89; 95% CI:0.54-1.48)
(Table 2).
Supplementary analyses
Because we have previously shown that the use of insulin
glargine was associated with a lower risk of diabetic
complications than intermediate- and long-acting human
insulins [13], we repeated all analyses on the subcohort of
patients who did not receive any prescription of insulin glargine
Figure 2.  Cumulative hazard according to the two treatment group of (A) Any diabetes-related complications (B)
Macrovascular complications, (C) Microvascular complications and (D) Metabolic complications.  
doi: 10.1371/journal.pone.0079762.g002
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throughout the entire study period. Baseline characteristics of
the unmatched and matched subcohorts are available in Table
S1.
For all endpoints, results were similar to those presented for
the entire study population. In particular in the unmatched
subcohorts, the adjusted HR estimates were 0.57 (95% CI:
0.46-0.72) for any diabetic complication, 0.57 (95% CI:
0.43-0.76) for macrovascular complications and 0.39 (95% CI:
0.22-0.69) for metabolic complications in rapid-acting insulin
users as compared with those on human regular insulin; no
statistical significant difference was found between the two
subgroups in relation to microvascular event rates (Table S2).
All results were confirmed after PS matched-pair analyses
(Table S2).
Discussion
The major finding of our study is that patients given rapid-
acting insulin analogues developed fewer diabetic
complications (especially, fewer macrovascular events) than
those given human regular insulin.
Due to the lack of randomization, significant differences in
baseline characteristics exist between the two treatment study
group. Patients on human regular insulin are expected to be at
higher risk of developing cardiovascular complications than
those on rapid-acting insulin analogue, because they were
older and more likely to use low-dose aspirin and
antiarrhythmic and antihypertensive agents. On the other hand,
patients treated with bolus insulin analogues were more often
men, reported a higher number of HbA1c tests and a higher
mean daily dose of all anti-diabetic agents than patients
receiving human regular insulin. Despite these differences
between the two study cohorts, the reduction of both primary
and secondary outcomes remained significant even after
adjusting for these and other potential confounders evaluated
in this study. These results were also supported by PS
matched-pair analyses performed on the two balanced
subsamples.
Moreover, based on our previous finding that a lower risk of
any diabetic complication was associated with the use of
insulin glargine [13] we carried out the analyses on the
subcohorts of patients who did not receive any prescription of
insulin glargine during the whole study period in order to
evaluate any possible interference of glargine use on the study
results. In this subgroup analysis, a statistically significant
reduction for any diabetes-related complication was still
observed in patients treated with rapid-acting insulin
analogues. Similarly, macrovascular and metabolic events
were markedly decreased in patients given rapid-acting insulin
analogues as compared with those receiving human regular
insulin.
Our findings were in line with a previous observation
suggesting that the use of rapid-acting insulin analogue
glulisine could be associated with a risk reduction of 24% for
macrovascular events in patients with type 2 diabetes as
compared with the use of human regular insulin [12]. In that
study, the assessment of the outcomes was based on ICD
codes registered by GPs only. The relevance of our study is
the use of a large-scale, population-based cohort and the
ability to draw information from a real-world setting through the
analysis of administrative data. As a matter of fact, the majority
of diabetes-related trials do not focus on significant
cardiovascular outcomes and are performed in study groups
that are not representative of the general diabetic population
[15]. We believe that the strength of administrative data for our
study question is in the ability to capture all acute diabetes
complication events that is extremely important for the
assessment of the quality of care in the real-world.
Nevertheless, we acknowledge that an observational study
using administrative data is prone to potential biases. In
particular, our findings may be subject to confounding by
indication due to the lack of randomization. In fact the
allocation of treatment is based on the clinical judgment of
Table 2. Cumulative incidence and Cox Proportional Hazard Ratios (HRs) of diabetes-related complications in patients
treated with human regular insulin or a rapid-acting insulin analogue.
 Unmatched cohorts Propensity-score matched cohorts
Complications
Human regular
insulin n (%)
Rapid-acting Insulin
Analogues n (%) Adjusted HRa (95% CI)Human regular insulin n (%)
Rapid-acting Insulin
Analogues n (%) HR (95% CI)
Any complication 286 (31.3) 235 (17.1) 0.56 (0.45-0.69) 165 (29.1) 132 (23.3) 0.73 (0.58-0.92)
Macrovascular 203 (22.2) 147 (10.7) 0.56 (0.43-0.72) 110 (19.4) 87 (15.4) 0.73 (0.55-0.95)
Cardiovascular disease 107 (11.7) 95 (6.9) 0.62 (0.44-0.86) 63 (11.1) 53 (9.4) 0.77 (0.54-1.10)
Peripheral vascular
disease 21 (2.3) 14 (1.0) 0.32 (0.14-0.75) 14 (2.5) 8 (1.4) 0.53 (0.22-1.27)
Cerebrovascular disease 75 (8.2) 38 (2.8) 0.55 (0.35-0.88) 33 (5.8) 26 (4.6) 0.73 (0.44-1.20)
Microvascular 43 (4.7) 53 (3.9) 0.73 (0.45-1.20) 27 (4.8) 26 (4.6) 0.89 (0.54-1.48)
Metabolic 52 (5.7) 37 (2.7) 0.36 (0.21-0.59) 35 (6.2) 21 (3.7) 0.55 (0.32-0.94)
Hyperglycemia 34 (3.7) 21 (1.5) 0.36 (0.21-0.59) 21 (3.7) 11 (1.9) 0.48 (0.23-0.99)
Hypoglycemia 19 (2.1) 16 (1.2) 0.51 (0.23-1.12) 14 (2.5) 12 (2.1) 0.62 (0.29-1.34)
IA= Insulin Analogues. Human regular insulin reference group. a Adjusted for variables reported in Table 1 plus mean daily dosage of both insulin and oral hypoglycemic
agents in quartiles.
doi: 10.1371/journal.pone.0079762.t002
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physicians and may be related to a different cardiovascular risk
profile between the two groups. However, all PS matching
resulted in full balance of all patients characteristics and is
likely to have minimized confounding by indication enhancing
the comparability of patients. In addition, Cox regression
analyses were conducted with macrovascular complications as
the endpoint after stratification for gender or age (<65 years
versus ≥65 years); the results remained essentially unchanged
when the association between study treatment and
macrovascular events was examined in the different subgroups
(Table S3).
The presence of unrecognized confounders could lead us to
over-estimate the magnitude of the association between
exposure and outcome as compared with the results of
randomized clinical trials. The analysis of confounders that
were included in the Cox-models was limited to variables
collected by administrative data. A good deal of information on
the degree of metabolic control, severity and duration of
diabetes and on lifestyle attitudes, which are known to
influence the likelihood of developing complications [16], is not
available in our data sources. Nevertherless, we attempted to
limit the role of these confounders by adjusting for age, sex,
concomitant drugs and the presence of microvascular or
metabolic events at baseline (the latter two factors may be a
proxy of duration and severity of diabetes); moreover we
reported all analyses in the two cohorts after PS matching.
Another limitation of our study is that our database does not
allow us to ascertain with confidence the type of diabetes as a
potential confounder. The higher proportion of younger patients
in the rapid-acting insulin analogue group suggests the
possibility of a higher prevalence of patients with type 1
diabetes. Therefore, we attempted to explore the effect of this
variable on our results by using the following criteria for
identifying type 1 diabetes cases: no records of oral
hypoglycemic agents, specific ICD9 code for type 1 diabetes
(250.x1 or 250.x3), diabetic ketoacidosis episode (250.x1),
age<40 year [17]. According to this analysis, the percentage of
type 1 diabetic patients was 5.6% in the human regular insulin
group and 15.7% in the rapid-acting insulin analogue group.
However, our results remain consistent after the inclusion of
this variable in all models or after the exclusion of type 1
patients from the analyses (data not shown).
Our findings could be explained by a better quality of care in
the group treated with bolus insulin analogues that could be
associated with a more favorable prognosis in that group [18].
However, we also adjusted for the number of HbA1c tests as a
proxy for the quality of diabetes care in all models.
Additionally, our study population included diabetic patients
free of macrovascular diseases at baseline, who may have
been misclassified because of medical errors in the medication
and diagnosis codes or the short baseline period (1 year).
However, this type of error does not seem to be very high
because the cohort of diabetic patients with macrovascular
disease at baseline represented about 30% of the overall
sample, which is consistent with results from previous
landmark studies [2,3]. Finally, because outcome data were
drawn from hospital discharges, these data can be
misclassified. However, outcome misclassification can be
expected to occur independently of the insulin exposure under
study and therefore a non-differential misclassification would
have biased the results of the study towards the null hypothesis
[19].
Despite these intrinsic limitations of observational data,
several speculative explanations for our findings should be
considered. In particular there are three demonstrated clinical
effects of the rapid-acting insulin analogues that could explain
why they may be more effective than the human regular insulin
in reducing the risk of diabetic complications.
1. Overall glycemic control may be better with rapid-acting
insulin analogues than with human regular insulin. These
agents can be injected immediately before the meals,
whereas human regular insulin should be injected 30-45
min before the meals [20]. In reality, most patients do not
follow the strict time injection required for the human
regular insulin administration and therefore in many cases
the PPG levels are not optimally controlled with this agent
[19,20]. In a randomized crossover study Annuzzi et al [21]
showed that insulin lispro, in combination with neutral
protamine Hagedorn (NPH) insulin, significantly reduced
HbA1c (0.2%) in type 1 diabetic patients. Furthermore, in a
large-scale multicentre trial Hermansen et al [22]
demonstrated that the combination of the basal-bolus
regimen (insulin detemir and insulin aspart) provided a
significant reduction in HbA1c by 0.22% when compared
with traditional insulins (NPH and human regular insulin) in
patients with type 1 diabetes after 18 weeks of treatment.
More recently, in a meta-analysis Mannucci et al [23]
showed that the use of rapid-acting insulin analogues in
type 2 diabetic patients provides a small but statistically
significant reduction of HbA1c in comparison with human
regular insulin. In our opinion the magnitude of the HbA1c
reduction found in these studies in patients treated with
rapid-acting insulin analogues is not sufficient to explain
our findings.
2. Another plausible account might be that the greater
beneficial effect of bolus insulin analogues on the
reduction of diabetic complications (particularly
macrovascular events), might be also attributable to their
ability to better control PPG excursions. In line with those
results, the Diabetes Intervention Study (DIS) [24] and The
San Luigi Gonzaga Diabetes Study [25] demonstrated the
importance of postprandial blood glucose control in
preventing cardiovascular events in patients with type 2
diabetes. Conversely, the HEART2D trial [26] did not show
any beneficial effect of specifically treating postprandial
hyperglycemia in relation to the risk of cardiovascular
events in diabetic patients. However, a post-hoc subgroup
analysis of the HEART2D on a specific population (older
patients) has found a lower risk of a subsequent
cardiovascular events associated with the use of prandial
insulin lispro [27]. In the light of these findings, the role of
postprandial hyperglycemia in the development or
progression of diabetic complication remains a sensitive
and controversial issue. Our results refer to a cohort of
diabetic patients without a recent cardiovascular event; in
this respect they don’t resemble the profile of the
Bolus Insulins and Diabetic Complications
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HEART2D cohort. Unfortunately, the potential role of PPG
levels in reducing the risk of developing long-term diabetes
outcomes cannot be evaluated in our study given the lack
of information on metabolic parameters in the database.
3. Finally, several studies have also shown a lower
occurrence of hypoglycemia with the use of rapid-acting
insulin analogues [28,29]. In our study we found a lower
risk of metabolic events in the rapid-acting insulin
analogue group. However, the incidence of hypoglycemic
events, when analyzed separately, was not statistically
different after adjusting for the covariates. Only
hypoglycemic episodes requiring hospitalization were
taken into account in our analyses and therefore it is
possible that we underestimated the overall incidence of
hypoglycemic episodes and the potential difference
between the two treatment groups in that these conditions
are more likely to be treated in an outpatient setting
[30,31]. Hypoglycemic events have been recently
recognized as important markers of cardiovascular risk in
diabetic patients [32].
Conclusions
This analysis from a real-world setting suggests that the use
of rapid-acting insulin analogues, in comparison with human
regular insulin, is associated with a lower risk of diabetic
complications and particularly macrovascular events. Future
trials may be required to determine the potential long-term
clinical benefits of bolus insulin analogues in preventing
cardiovascular diseases in diabetic patients.
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